A new experimental compound known as PP405, sometimes referred to in scientific literature as Z791, is gaining significant attention in the field of hair loss treatment following encouraging early clinical trial results. The compound is currently being investigated as a potential therapy for androgenetic alopecia, the most common form of pattern hair loss.
 |
| PP405 experimental hair loss treatment showing hair regrowth in clinical trials |
Although PP405 is not yet commercially available and remains an investigational drug, researchers believe it could represent a new generation of hair regrowth treatments with a fundamentally different mechanism of action compared to existing therapies such as minoxidil and finasteride.
🔬 A Novel Mechanism of Action
Unlike traditional hair loss treatments, PP405 is a small-molecule compound designed to directly activate hair follicle stem cells.
- Lactate Metabolism Activation: PP405 stimulates lactate production inside follicular stem cells.
- Reactivation of Dormant Follicles: This metabolic signal encourages resting follicles to re-enter the anagen (growth) phase.
Researchers have emphasized the importance of mitochondrial metabolism in regulating stem cell activity, with PP405 specifically targeting this pathway.
🧪 Developer and Scientific Background
PP405 is being developed by Pelage Pharmaceuticals, a biotechnology company spun out of academic research conducted at the University of California, Los Angeles (UCLA).
Between 2024 and 2025, Pelage Pharmaceuticals initiated Phase 1 and Phase 2 clinical trials to evaluate the safety and preliminary effectiveness of PP405 in both men and women affected by androgenetic alopecia.
📊 Latest Clinical Trial Results (Phase 2a – 2025)
- Increased Hair Density: About 31% of participants achieved over 20% hair density improvement within 8 weeks.
- Rapid Response: Visible regrowth appeared in some users after only 4 weeks.
- Regrowth in Bald Areas: Terminal, pigmented hair regenerated in previously bald regions.
🛡️ Safety Profile and Side Effects
- No systemic absorption: Blood tests confirmed PP405 remains localized in the scalp.
- Minimal irritation: No significant scalp inflammation was reported.
Because PP405 does not interfere with hormonal pathways, it may avoid side effects associated with some oral hair loss medications.
⏳ Development Timeline and Availability
- Phase 3 Trials: Planned for 2026 following approximately $120 million in funding.
- Expected Market Release: Potential availability between 2027 and 2028, pending FDA approval.
🔍 Comparison With Existing Hair Loss Treatments
| Feature | PP405 | Minoxidil / Finasteride |
|---|---|---|
| Mechanism | Stem cell activation | Blood flow / DHT suppression |
| Speed | 4–8 weeks | 4–6 months |
| Hair Type | Terminal hair | Often vellus hair |
| Systemic Exposure | None detected | Possible |
🧾 Current Status
As of January 2026, PP405 remains an experimental treatment and is not approved for commercial use. Larger Phase 3 trials are required to confirm long-term safety and effectiveness.
❓ Frequently Asked Questions
Is PP405 available to the public?
No. PP405 is currently only available through clinical trials.
How is PP405 different from minoxidil?
PP405 directly activates follicle stem cells, while minoxidil mainly improves blood flow.
Does PP405 affect hormones?
Current data indicates that PP405 does not interfere with hormonal pathways.
According to a press release from Pelage Pharmaceuticals, PP405 activates follicle stem cells and shows a rapid response in Phase 2a trials.
